Sodium p-aminosalicylate enteric-coated tablets

It has an antibacterial effect only on Mycobacterium tuberculosis. This product is a congener of para-aminobenzoic acid (PABA), which inhibits the growth and reproduction of Mycobacterium tuberculosis by competitively inhibiting the synthesis of folic acid.

Sodium p-aminosalicylate. Its chemical name is: 4-amino-2-hydroxybenzoic acid sodium salt dihydrate. Molecular formula: C7H6NNaO32H2O, molecular weight: 211.14.

This product is an enteric-coated tablet, which appears white or off-white after removing the enteric coating.

It is suitable for pulmonary and extrapulmonary tuberculosis caused by Mycobacterium tuberculosis. This product is only effective against mycobacteria. When used alone, Mycobacterium tuberculosis can quickly develop drug resistance to this product, so it must be used in combination with other anti-tuberculosis drugs. When streptomycin and isoniazid are used in combination with this product, it can delay the development of drug resistance of Mycobacterium tuberculosis to the former two. This product is ineffective against atypical mycobacteria. It is mainly used as a second-line anti-tuberculosis drug.

Adults take 4 to 6 tablets orally at a time, 16 to 24 tablets per day, 4 times a day; children take 0.2 to 0.3 g/kg per day according to body weight, divided into 3 to 4 times. The daily dose for children should not exceed 12 g.

1. Those with a higher incidence: allergic reactions include itching, rash, drug fever, asthma, and eosinophilia. 2. Those with a lower incidence: gastric ulcer and its bleeding. Others include hematuria, proteinuria, liver damage, and granulocytopenia.

It is contraindicated for those who are allergic to this product.

1. Para-aminobenzoic acid and this product have antagonistic effects, and the two should not be used together. 2. This product can enhance the effect of anticoagulants (coumarin or indandione derivatives), so the dose of oral anticoagulants should be appropriately adjusted when using para-aminosalicylic acid or after using it. 3. When used in combination with ethionamide, adverse reactions may increase. 4. The combination of probenecid or sulfinpyrazone with aminosalicylic acid can reduce the secretion of the latter from the renal tubules, leading to increased blood drug concentrations, prolonged duration, and toxic reactions. Therefore, when aminosalicylic acid is used in combination with probenecid or sulfinpyrazone or after the combination, the dose of the former should be appropriately adjusted, and the patient should be closely followed up. However, most people do not use probenecid as an auxiliary drug for aminosalicylic acid treatment. 5. Aminosalicylic acid may affect the absorption of rifampicin, resulting in a decrease in the blood concentration of rifampicin. Patients must be informed that they should be at least 6 hours apart when taking the above two drugs. 6-Aminosalicylates and vitamin B12 can affect the absorption of the latter from the gastrointestinal tract when taken together. Therefore, patients taking aminosalicylic acids may have an increased requirement for vitamin B12.

Keep away from light and store in sealed container.

0.5g